Moods Disorders Completed Phase 3 Trials for Paliperidone (DB01267)

Also known as: Mood Disorders / Mood Disorder

IndicationStatusPhase
DBCOND0058256 (Moods Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00309699A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I DisorderTreatment